在临床实践中我应该使用哪种血浆pTau217检测方法？揭开潘多拉魔盒的神秘面纱。
Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified.
作者信息
Toniolo Sofia
机构信息
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.
Cognitive Disorder Clinic, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
出版信息
Brain. 2025 Feb 3;148(2):354-356. doi: 10.1093/brain/awaf007.
Abstract
This scientific commentary refers to ‘A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests’ by Warmenhoven (https://doi.org/10.1093/brain/awae346) and ‘Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison’ by Pilotto . (https://doi.org/10.1093/brain/awae368).
摘要
本科学评论参考了瓦尔门霍芬的《关键血浆磷酸化tau 217生物标志物检测的全面直接比较》（https://doi.org/10.1093/brain/awae346）以及皮洛托的《阿尔茨海默病中的血浆p-tau217：Lumipulse和ALZpath SIMOA直接比较》（https://doi.org/10.1093/brain/awae368）。
相似文献
1
Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified.在临床实践中我应该使用哪种血浆pTau217检测方法？揭开潘多拉魔盒的神秘面纱。
Brain. 2025 Feb 3;148(2):354-356. doi: 10.1093/brain/awaf007.
2
The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis.在检测脑淀粉样变性方面，血浆pTau217与Aβ42的比值比单独测量更具优势。
medRxiv. 2025 Jan 10:2024.12.07.24318640. doi: 10.1101/2024.12.07.24318640.
3
On-demand storage and release of antimicrobial peptides using Pandora's box-like nanotubes gated with a bacterial infection-responsive polymer.按需存储和释放抗菌肽的 Pandora 盒状纳米管，其由细菌感染响应性聚合物控制。
Theranostics. 2020 Jan 1;10(1):109-122. doi: 10.7150/thno.38388. eCollection 2020.
4
Prospective evaluation of plasma pTau stability for the detection of Alzheimer's disease in a tertiary memory clinic.在三级记忆门诊对血浆磷酸化tau蛋白稳定性用于阿尔茨海默病检测的前瞻性评估。
Alzheimers Res Ther. 2025 Jul 5;17(1):150. doi: 10.1186/s13195-025-01779-7.
5
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.血浆pTau181/Aβ42、pTau217/Aβ42比值及个体测量值在检测脑淀粉样变性中的比较性能
EBioMedicine. 2025 Jun 12;117:105805. doi: 10.1016/j.ebiom.2025.105805.
6
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织（EORTC）癌症贫血患者促红细胞生成蛋白使用指南：2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
7
Opening Pandora's box - key facilitators of practice change in detecting and responding to childhood adversity - a practitioner perspective.打开潘多拉的盒子 - 发现和应对儿童逆境方面实践变革的关键促进因素 - 从从业者的角度。
BMC Pediatr. 2024 Jul 18;24(1):461. doi: 10.1186/s12887-024-04918-5.
8
[Good clinical practice and Pandora's box (II). Informed consent].[良好临床实践与潘多拉魔盒（二）。知情同意书]
Med Clin (Barc). 1997 Jan 11;108(1):19-22.
9
[Good clinical practice and Pandora's box (and III). Data reliability].[良好临床实践与潘多拉魔盒（以及第三部分）。数据可靠性]
Med Clin (Barc). 1997 Jan 18;108(2):65-7.
10
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中，在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值：对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
本文引用的文献
1
Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.阿尔茨海默病中的血浆磷酸化tau217：Lumipulse和ALZpath SIMOA的直接比较
Brain. 2025 Feb 3;148(2):408-415. doi: 10.1093/brain/awae368.
2
Plasma p-tau immunoassays in clinical research for Alzheimer's disease.血浆p-tau免疫测定在阿尔茨海默病临床研究中的应用
Alzheimers Dement. 2025 Jan;21(1):e14397. doi: 10.1002/alz.14397. Epub 2024 Dec 3.
3
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.关键血浆磷酸化tau 217生物标志物检测的全面直接比较。
Brain. 2025 Feb 3;148(2):416-431. doi: 10.1093/brain/awae346.
4
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.用于阿尔茨海默病病理的主要血液检测的头对头比较。
Alzheimers Dement. 2024 Nov;20(11):8074-8096. doi: 10.1002/alz.14315. Epub 2024 Oct 12.
5
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
6
Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.可接受的淀粉样蛋白病理血生物标志物检测性能——来自全球阿尔茨海默病首席执行官倡议的建议。
Nat Rev Neurol. 2024 Jul;20(7):426-439. doi: 10.1038/s41582-024-00977-5. Epub 2024 Jun 12.
7
NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing.NULISA：一种具有阿伏伽德罗灵敏度和高多重检测能力的蛋白质组学液体活检平台。
Nat Commun. 2023 Nov 9;14(1):7238. doi: 10.1038/s41467-023-42834-x.
8
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases.基于血浆 p-tau217 的两步工作流程，对淀粉样β 阳性进行筛选，仅对不确定病例进行进一步确认性检测。
Nat Aging. 2023 Sep;3(9):1079-1090. doi: 10.1038/s43587-023-00471-5. Epub 2023 Aug 31.
9
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
10
Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer's disease.用于阿尔茨海默病血浆生物标志物的Lumipulse免疫测定法的分析前变异性。
Clin Chem Lab Med. 2022 Nov 28;61(3):e53-e56. doi: 10.1515/cclm-2022-0770. Print 2023 Feb 23.
Zotero 插件